It stayed with you when you entered the Ashford Global boardroom, where sixteen executives waited around a polished table long enough to seat a dynasty.
It stayed with you when your CFO began discussing a crisis involving your company’s most profitable medication, Veylora, a rare-disease drug whose annual treatment cost had recently crossed $480,000 continue reading …